GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » EPS (Diluted)

Affymax (Affymax) EPS (Diluted) : $0.06 (TTM As of Jun. 2014)


View and export this data going back to 2006. Start your Free Trial

What is Affymax EPS (Diluted)?

Affymax's Earnings per Share (Diluted) for the three months ended in Jun. 2014 was $0.19. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 was $0.06.

Affymax's EPS (Basic) for the three months ended in Jun. 2014 was $0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2014 was $0.06.

Affymax's EPS without NRI for the three months ended in Jun. 2014 was $-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2014 was $-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Affymax EPS (Diluted) Historical Data

The historical data trend for Affymax's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax EPS (Diluted) Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.06 -0.57 -1.84 -2.57 -0.39

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 -0.05 -0.04 -0.04 0.19

Competitive Comparison of Affymax's EPS (Diluted)

For the Biotechnology subindustry, Affymax's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's PE Ratio distribution charts can be found below:

* The bar in red indicates where Affymax's PE Ratio falls into.



Affymax EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Affymax's Diluted EPS for the fiscal year that ended in Dec. 2013 is calculated as

Diluted EPS (A: Dec. 2013 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-14.424-0)/37.448
=-0.39

Affymax's Diluted EPS for the quarter that ended in Jun. 2014 is calculated as

Diluted EPS (Q: Jun. 2014 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(7.209-0)/37.490
=0.19

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymax  (OTCPK:AFFY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Affymax EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Affymax's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010